MedTrace Logo

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

NCT01972672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2021-01-27

No results posted yet for this study

Summary

The primary objective of the study is to assess the time to progression (TTP) in patients with advanced HCC treated with Icaritin .

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Icaritin

Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • NanJing PLA 81 Hospital

    collaborator OTHER

  • 307 Hospital of PLA

    collaborator OTHER

  • Qingdao University

    collaborator OTHER

  • Beijing Shenogen Biomedical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yan Sun, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • ShuKui Qin, MD · NanJing PLA 81 Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-08-31
Completion
2017-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01972672 on ClinicalTrials.gov